Cogent Biosciences, Inc. — Investor Relations & Filings

Cogent Biosciences is a clinical-stage biotechnology company focused on developing and commercializing precision therapies for genetically defined diseases. The company designs best-in-class, small molecule therapeutics to target the underlying genetic mutations that cause illnesses such as cancers, rare diseases, and autoimmune conditions. By leveraging validated biology, Cogent aims to address significant unmet medical needs, often by improving upon existing drugs with clear limitations or safety concerns. The company's lead clinical program is bezuclastinib. Cogent's research is dedicated to pioneering novel treatments that can transform the lives of patients.